Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
CA 2829581 C · Owner: Institut Pasteur · Inventors: Delebecque, Frederic; Mollet, Lucile; Tangy, Frederic
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 20, 2003 and granted May 1, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.